BioAge Labs advances BGE-102 with strong Phase 1 data

The latest announcement is out from BioAge Labs, Inc. ( (BIOA) ).

On January 12, 2026, BioAge Labs reported additional positive interim Phase 1 data for its lead candidate BGE-102, a brain-penetrant NLRP3 inhibitor in development for patients with elevated cardiovascular risk. In a multiple ascending dose cohort of obese participants with high baseline inflammation, a 120 mg once-daily regimen of BGE-102 achieved an 86% median reduction in hsCRP by Day 14, with 93% of treated participants reaching hsCRP levels below 2 mg/L, a threshold associated with reduced cardiovascular events. The drug also produced meaningful declines in IL-6 and fibrinogen, showed strong IL-1β suppression consistent with robust target engagement, and was reported to be well tolerated, while the company secured a patent covering additional composition of matter and a novel NLRP3 binding site. Building on earlier favorable safety, pharmacokinetic, and brain-penetration data disclosed in December 2025, these results bolster BioAge’s positioning in inflammation-driven cardiovascular disease and support its plan to complete the Phase 1 trial and advance BGE-102 into a roughly 100-patient Phase 2a proof-of-concept study in obesity with cardiovascular risk factors in 2026, with key readouts expected later in the year.

The most recent analyst rating on (BIOA) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on BioAge Labs, Inc. stock, see the BIOA Stock Forecast page.

Spark’s Take on BIOA Stock

According to Spark, TipRanks’ AI Analyst, BIOA is a Neutral.

The score is held back primarily by weak financial performance—large losses and substantial cash burn despite modest revenue growth—partially offset by a currently supportive balance sheet. Technically, the stock shows strong upward momentum (above key moving averages and positive MACD), though overbought RSI raises near-term volatility risk. Valuation remains challenged due to unprofitability, while the positive Phase 1 update is a meaningful supportive event.

To see Spark’s full report on BIOA stock, click here.

More about BioAge Labs, Inc.

BioAge Labs, Inc., based in Emeryville, California, is a clinical-stage biopharmaceutical company focused on developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. Its lead asset, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor aimed at treating cardiovascular risk factors, alongside additional preclinical programs including long-acting injectable and oral APJ agonists for obesity and other metabolic aging pathways.

Average Trading Volume: 522,413

Technical Sentiment Signal: Buy

Current Market Cap: $499.1M

For detailed information about BIOA stock, go to TipRanks’ Stock Analysis page.